Skip to main content

Bioxytran Stock Forecast, Price & News

-0.01 (-5.56 %)
(As of 05/13/2021 10:10 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume7,700 shs
Average Volume5,122 shs
Market Capitalization$17.13 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BIXT News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter.

Bioxytran logo

About Bioxytran

Bioxytran, Inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. The company's lead pharmaceutical drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. Its products also include BXT-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. The company was founded in 2017 and is headquartered in Newton, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:BIXT
Phone617 454 1199
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value($0.01) per share


Net Income$-1,860,000.00




Market Cap$17.13 million
Next Earnings Date5/19/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1906th out of 2,032 stocks

Pharmaceutical Preparations Industry

748th out of 768 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Bioxytran (OTCMKTS:BIXT) Frequently Asked Questions

What stocks does MarketBeat like better than Bioxytran?

Wall Street analysts have given Bioxytran a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bioxytran wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bioxytran's next earnings date?

Bioxytran is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for Bioxytran

Who are Bioxytran's key executives?

Bioxytran's management team includes the following people:
  • Dr. David Platt, Chairman, CEO & Pres (Age 68, Pay $72k)
  • Mr. Ola Soderquist C.M.A., C.P.A., M.B.A., CPA, CMA, CM&AA, CFO, Treasurer & Sec. (Age 59, Pay $72k)
  • Ms. Elena Chekhova, Chief Scientist

Who are some of Bioxytran's key competitors?

What other stocks do shareholders of Bioxytran own?

What is Bioxytran's stock symbol?

Bioxytran trades on the OTCMKTS under the ticker symbol "BIXT."

How do I buy shares of Bioxytran?

Shares of BIXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bioxytran's stock price today?

One share of BIXT stock can currently be purchased for approximately $0.17.

How much money does Bioxytran make?

Bioxytran has a market capitalization of $17.13 million.

How many employees does Bioxytran have?

Bioxytran employs 2 workers across the globe.

What is Bioxytran's official website?

The official website for Bioxytran is

Where are Bioxytran's headquarters?

Bioxytran is headquartered at 233 NEEDHAM ST SUITE 300, NEWTON MA, 02464.

How can I contact Bioxytran?

Bioxytran's mailing address is 233 NEEDHAM ST SUITE 300, NEWTON MA, 02464. The company can be reached via phone at 617 454 1199.

This page was last updated on 5/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.